Preclinical CRO Market Size Worth $8.4 Billion By 2028 | CAGR: 8.1%: Grand View Research, Inc.

News provided by

Feb 18, 2021, 04:35 ET

SAN FRANCISCO, Feb. 18, 2021 /PRNewswire/ -- The global preclinical CRO market size is expected to reach USD 8.4 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.1% from 2021 to 2028. The market is expected to witness lucrative growth over the forecast period due to increasing R&D expenditure and growing outsourcing trend. The increasing volume of new drugs entering the preclinical phase is also anticipated to boost the market growth over the forecast period.

Key suggestions from the report:

By service, the toxicology testing segment accounted for the largest share of 61.1% in 2020 due to its significance in Investigational New Drug (IND)-enabling studies
Based on end-use, the government and academic institutes segment is anticipated to register the highest CAGR of 8.4% over the forecast period due to improving government initiatives toward healthcare, especially in developing economies
North America dominated the market in 2020 with a share of 47.7%. Significant healthcare expenditure on R&D is one of the major factors driving the market in this region

Read 240 page research report with ToC on "Preclinical CRO Market Size, Share & Trends Analysis Report By Service (Toxicology Testing, Bioanalysis & DMPK Studies), By End-use (Biopharmaceutical Companies, Government & Academic Institutes), And Segment Forecasts, 2021 - 2028" at: https://www.grandviewresearch.com/industry-analysis/preclinical-cro-market

The market is undergoing a series of mergers and acquisitions, resulting in the improvement in full-service capabilities and international reach of larger companies. For instance, in 2019, WuXi AppTec acquired Pharmapace. On the other hand, mid-sized and smaller contract research organizations (CROs) are focusing on niche sectors and are providing a personalized approach to their sponsors. Various companies are focusing on research and development of new drugs, and therefore are outsourcing these activities to launch efficient CRO services in the market. This, in turn, provides a positive atmosphere for joint ventures among market participants owing to the preference of sponsors to maximize their benefits.

The COVID-19 epidemic is ever increasing since it was first identified in China in December 2019. Until January 20, 2021, more than 96.7 million cases of COVID-19 were reported globally, with more than 2,068,303 deaths across the globe. This pandemic has fast-tracked the development of vaccine and drug testing. There are currently more than 50 COVID-19 vaccine candidates in preclinical studies as well as trials.

North America held the largest share of 47.7% in 2020. Significant investment in healthcare R&D, coupled with well-developed healthcare infrastructure in the U.S., is contributing to the largest share of North America. Asia Pacific is projected to expand at the fastest CAGR of 12.0% over the forecast period.

Grand View Research has segmented the global preclinical CRO market on the basis of service, end-use, and region:

Preclinical CRO Service Outlook (Revenue, USD Million, 2016 - 2028)

Bioanalysis and DMPK Studies
Toxicology Testing
Others

Preclinical CRO End-use Outlook (Revenue, USD Million, 2016 - 2028)

Biopharmaceutical Companies
Government and Academic Institutes
Medical Device Companies

Preclinical CRO Regional Outlook (Revenue, USD Million, 2016 - 2028)

North America

U.S.
Canada

Europe

U.K.
Germany
France
Spain
Italy
Netherlands
Belgium
Switzerland
Russia
Sweden

Asia Pacific

India
Japan
China
Australia
South Korea
Malaysia
Indonesia
Singapore
Philippines
Thailand

Latin America

Brazil
Mexico
Argentina
Columbia
Chile

Middle East & Africa

South Africa
Saudi Arabia
UAE
Israel
Egypt

List of Key Players of Preclinical CRO Market

Envigo Corporation
MPI research
Eurofins Scientific
PRA Health Sciences, Inc.
Wuxi AppTec
Medpace, Inc.
Pharmaceutical Product Development (PPD), LLC
PARAXEL International Corporation
ICON Plc
Laboratory Corporation of America, Inc.

Find more research reports on Pharmaceuticals Industry, by Grand View Research:

Regulatory Affairs Outsourcing Market – The global regulatory affairs outsourcing market size was valued at 6.3 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 11.9% from 2021 to 2028.
ADME Toxicology Testing Market – The global ADME toxicology testing market size was valued at USD 4.33 billion in 2017 and is expected to register a CAGR of 11.4% over the forecast period.
Bioanalytical Testing Services Market – The global bioanalytical testing services market size was valued at USD 3.3 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 8.6% from 2021 to 2028.

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter

SOURCE Grand View Research, Inc.